About Leucine-rich repeat transmembrane protein 3
Leucine-rich repeat transmembrane protein 3 (LRTM3) is a protein
from Homo sapiens identified by UniProt accession
Q8NDH2, 7081 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | Leucine-rich repeat transmembrane protein 3 |
| UniProt accession | Q8NDH2 |
| Gene | LRTM3 |
| Organism | Homo sapiens |
| Length | 7081 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- genetic disorder · score 0.12
- Red cell distribution width · score 0.06
- PHF-tau measurement · score 0.02
- gastric adenocarcinoma · score 0.01
- ulcerative colitis · score 0.01
- oral squamous cell carcinoma · score 0.01
- renal cell carcinoma · score 0.01
- neoplasm · score 0.01
- Tetralogy of Fallot · score 0.00
- prostate carcinoma · score 0.00
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (7081 residues)
MSKQYYSFKK GVGSGLEDNT FMTLWDFLES WIIQNDWVAI FFIILLGIIF EIILMKACAS FWKKPTLPEK GSSDVQETED SCPKSRKLAP ENWSVINSSS GERVGTFLEK RITSSLTSEE KECNFEDRIL FSREILWSGT SESEDQVSPS SESHVPSSNG ISSSLPLFYS EVEETCLSHT EHPDREYETI QFSSKKLFSM MKTNKNKNSG FSSDLSFSAS RFTVENEDLD VAPCPLAHLF LSRDQVRLLE ENVRNQIPSK PKTKLGSRTT YQCSRSQESL NQNQPSVGMV ISVQAQDSFP GQNAFQNQGL YEVQFTSQAQ YINHNQESIK SQPESKASNF AQPEDVMKKP FSSSTQDSFQ SQDLDRNQHF VEVPSIVEAK YSVKGLESDE HLGEDQHCVW FIDSNKVKYS IKGQDTIFKN AEFLVLTLNP NLVTEDMPQL RSVKAQGQQQ IVSSELNQDS VYSSVPLLST IKGQKNRRKT PDSKSKLSLN VPSLKAKKTP TSQVFQITVC HTLKNRNELG CKNNTEKKEL HERKDISDIA LHLISVSKLI LPYVKNYSRK QLVKVMPGLI KCGHFLQKQN KSPDTEKINY AGPLEETGIS DITKKEKEYD KENKRLKNIS PKMLPQLEQS FMVNTVQLKA PCLLVETNGK SKESLKDSIT QAKGIGITEF HVLNSKKPFD LHIPKHKTSL EEAISKPMQK LVSSPEMESN NRMKIQEDLQ SSENSHLQLS NGEELPTSTP KTQRCFPREN TQKQKDFLEL VLELSNVGLL ISPGSKMHKS SEELEAIKIQ VNTESVNLKE SKPLILNVTE DSDLRESEEL ECNTGSNITN MHQDKETSDA FHSATYTTIS QLPDTETHSI SKAKADTLRI IRLSHSASKQ EKLPDEKETQ NAEYIDKSCT FKKPQQCDRK EQEKEANSEL TQGFRFSIHL KQKPKYVKFQ MEQISSGSSK APNKEQEVQP QTLSTQTILE NSPCPMMDPF QVEKVKQSTD RPTDRESAGD PKNPLTMPEN LPVGELLIET TEYSVPFGGN LQKTTDSHIA EEKEDVKRYL PAVALGSFNN HLLTLPYFKR QEIKKKLSET KSVLSVKYVI MKVKKPAISL MPYINICGTS NHRKKMGGNF EIIIKQILQD KIAAGMLLNV IYPPMSILPN TRMYSRLNAE NHSHIKLVQE ESQIEREEKY PYFINEGNES QNTLDAKLQD EVKGVKETLP KAVLHDSCNL GLDAHLEKEI KTEKEMHQPI PFTETIIESV VSPIMELSHA ENVKSTQKTQ TDCKCTADSE TPSPISGKSL IGDPLNQTRE SYIPSNGSDT REMGYCFAEE KTEIPKDLPA TSPETFNYCT PVLSCSKVMK KRVTFALTTS TAKPKCVNTK AVKPSISETV SVTSHRKKSE LDFKTKFKKI NQTKGLVPEC LNTLCSPMHS RLQREFCLPA SQLKQGETAD KTYTDVFAKN SISHDREEKL QDGKEEEHKV LLEAAPQLSQ HLGSEAGQMK EIHLESDPVL NCLTLELHIN GQRLQHQTGF EQTTLETSLQ MGPLEAEELQ KANETENDIK VLGGPKIPPP KALQALENSD GLILNAYQKD NELVKSDEEL NQPGSTNIQV QPQTHFTQTI LKSTSCPTLD QFPFEKVESH VRFSPLKSGE AKVDEIIFYA REGGISSDSS HQKEQAGGTE KKETAIFGSC MPALSTPKTT RNLKQFSDMK TLVNPKCGII KAKKPSISYM LNIRAGAGPK RRKELSCNLT TKMKELHQGK KGVDETYAFL TMTPDINKYS KVETEKDTLR EKRLSSTQVK QDTSPHEDSI TSRDIKETLL QDEEQEERKQ EALLKVIPQH LQHFMFRSGQ GKDLDFHKLE NQGSRKILFV TKQDVPQQLQ PAEPIQREET KKCLQTQNGT ICTVNSKLLP LKSEDSVNGE VLTGAIKRGV PTDRKCMGEQ HNSGKGEKAE FNKDLQATVL ELQKSPHGGE AQKANLTDME SGSSNAMNMN VQHEREDKNI QKMLTESVPC YSQHLRFSTH QMKDPDPCKS GSEPKSPEGR SWNLSHIVQK TKQETHFRET VLEPISGYMM KQSPHMQEGI KCMEGLKTSF PKTGKSKIGS IPRDTPWDEN PRRKWDSSIS EKTAWNQKNL QTVLKPLDFS SLMSSEYESR SYTLEFIGKK SMSPKCVTLK AKQLRILQLF NIIRYSTENH RKKKQHRFKY KMKGKQWYTS IGEALLSATE YAKSTTSKSM IDKLLYNTAA RCILSNRTRR QNLDGHITEE KEEVQENVAA IFLGLLDFFM PVLSDSKNQR NTAQLSEKEI IFNAKCLTMK EKKSSISQIH KINRESTRKH RKKCKSYLKT VSNRKCQENH GHITEEEEEV QENSPATFLG PLDFFMPVLS DSKNQINTIQ LSERKIILNP KCLTMKEKKP PISQIHKISG QFTTKHRKKL ESNLKTKLKA MWQGENVADT FPNTTSFTPD SSDIKRQSGF QTEIDMRISG LSHTQPTQIE SLAEGIARYS DPIDKRRTSN LVKGAKLHDR ESGEEKQEHL TEMDPFYAEN FMANTYLRKD RHLGKSEDVL LGETFFSKSQ IYKGNSEKNV KIEKNKNGKE SLKVGLARME KSDNCAELSE ATDDAISNKY DKQNIGHSVL KENAFCNLAA IVPDSVGRHS PASEEMKRQN GRLKMADRSS PQGRPLQAKQ SAVSQSPDTA GYAVVSNNKE QKQNFKAQKT EAEVDLIDQE AKINVAEEFN PESVFFSKIH PLQIENKKEF KTADWKTRAD PKTFALPKKQ QELCVSGTIW SYPNPYTSIS PKIIRHKDKA KTADVESTMH TKQIKLKAKR ITVSQLLEYG TASNKKELRG NIQQQKSFQL SKNAVHRVLK AVYDSGYCVS SIKKLTEVKM EKDKPKDRTC ILPQPKLEKP LKEMQRSLSG CTDMSSILRK QEQDIREKEQ KHQSISEDIS QYYIGPLRIS SQQINYSSFD APRIRTDEEL EFLIAQRAKE KDVGIAKHSV SIPWEREGSK RLDIPLNSKG QNIFFTELDT SQQKTCQEQE LLKQEDISMT NLGSMACPIM EPLHLENTGK VTEEEDVYIN RKISSHVLGK EGLKETDIFV GSKGQKFLCT NSEVQHKVPA EQKEQVNPDH VPESILDSES FLSKDPLHLK QAVNTARKEN VTISESFNEN LWGKEQSKLD ITLKSNRQKM DFSKKLRMKH LSNYYQNKEN ILESVLPCIL HQLYIENPKK EGSAEEIMSS KVLSPMVEKA SHEVGIPVDQ PPCSEGIHLN IKGRKEHPQE STHEAFPASV SHSLMDVLQI KSPKVKKALK AINSLGYLTS NTKGIGLLFP RQAEKEEKYT YKALPKPASH SKTDLFQFNA SMQQEKLDAM DIPHYDYLTS QTREAVKQMD VIVGYTQNSK KRQDLLKTGQ KWQYLPISYE NFWEHISCPQ KYPCLLQHLM PQEKEALSEG GNLSSRTPGL DLFSADQLST ITKNRLEWIV PLISPRQMKK QDSMLPLGSY HKTIKYASLL FPKGMKSSDG VQVFDLISNN SSPKLRLGKK IETQKANEKV QKEVCLPITL HSLSASMPIL QESKGQKDSV EQVIRKGVIC HKRRTSKWKK SVFSHILNTS DCGASSNRLE MQWNMTDKMV NVKHRMSEID LVAAKICESI LSLPHFKLNK ETIDGVISSN VKSTKQHISQ GKNDRVKAMD MKRIKSPNII LKPRKSSLSH ILSIKEFPLL LDIIKQEGKM QEGKGKSSMK LTNLCTSLPS LSHSNSNSRT KAGKDKSGTL KGCLPPLKLQ ASSNARRVSS AESINRDSLS NVIESKCFPQ KKKEDRENIV DVKDVMGLKC ITLKGKKSLF RHLLHGKEPQ RSNKKLEKMT QEDESNLNVV QNKLCASILS PPHLEWNPRI KEVYMRGITR FCLSSSTQQE LSDTMEKCEQ PIDDSLSSIE KAKHMPQKDK DRVEKALEKI MHSKRIALEV KQPSIFQELE LNIKEKGGKI QEDKEVEIWS KPFASISFLP YSKVGTIEGE EAMRIKMRSS FSQPNLQESS DTEKTAYEKC ISDNISNSVK KALESILQKE QRQKMEKIRA LKKMKSSISQ GIQLDIKEQE KRIEHIKGEP SVLLTNACAS IPSPSHLQLD TRREKAEYVT EITRYYLPEL SHQKSSEAGE KADGVASKGD ITIKVQKAKD YMQQKEDDEV KISAKKDIMH PEDKGLKAKK ALSQDLPLNT KEPGKMDQEA QEQGKEDREG EEQGKEDRRG AGQEKVDRED KEQGKMDHEV EEQQKADGVG IEQGKMDGDK NEQERVLFLY LPSNSSLTHY ILDTRIEGEE DQQGIIRPGI LQPRHQKSSE TGKKANGVPS EGDSASEVQK AKDYMQQKEE DEVKISAEKD LMHPEDKDLK GKKALSQNLP LNPKEPGKRD GEGQEQGKED GEGEEQGNRD GETEEQQQAD GVGTEQEKRD GHKSKQETVL FLHLPSESSL TCYELNTRKE GEEDLQGIIK SATLQLRQQK SFDAGKIAHT KSFGVDSSND VKTVQEYKPQ KEVDRGKTVS VDYIMQPEGT IFEAEQLSLP HTLNIPGSSG SKTREVLTNI KEKLRHVQER KSELDVFLTI PSLSHCKLDK RTAGKKEEQG VTRSFLPPSW HMESSDTGKL KYTLSYLNDI TGDSNRTKYM AQIQKDKANI SEKSVMHPEY IAVKAEKSPL SHILKTKELQ VNISQQGEKA QEGEVEIVVL LSKTCPFVTS SAFLELDSIK EEEGEPRITR SFMPHLEIQE SLPSRQTAPT KPTESLVKKE KQLLPQKEDR VQTVSMHGLM HPNGAVFKAK TSAPPQVFSI TEHSPLSKRK EPQWGMKERA GQKQDRTGRP HVILTKTHPF MPSLSHHRFS PSQPKLPISS GAGKSRLANS NEGISSHKVI LKANQQMPYK EAKDRVKIEG REGRILPKRI HLRAEALPLA LLCNGKNYSL HIEEQGEGVQ ESKKEPGVVP RKSASFPPPP FYLNCDTRRN EKEGTLGKTQ FSFPPLKIQD SSDSGKKAYT ESLHGYTLSN SKGPVQPTAQ GEEKGGLRID MEDKMLPKCT DLKAKQLLLS DILNTKKLQW KSKEQKRKIQ EDKNKQVKGL PSINTSLLTP PYLKFDTTEG QENVIRIAKV SLPQSRSKES SDAGRIACPE ATHGELSSDV KQLKAHLLQK EEKDREKVAD MTSVLDPNKM YLKAKKSPVL HTHSFSDLQW KTREQEEEKV QKVKSGPGVM LSKSPSRSSP LHLNVNTGFQ EESIPILTRP SFPLVKLQVS PDTEGGTCIR PIAGDILIYL QKGKHVSQNK EEDDVQIVSI LIFPKHQEEK VQECEGEPGV VLTKSTSLPS LSQLELDKET HLGNEMLRLK RPILRRISHI GETVHRESVV GDIPKDVKNE KQHIPQKEER NQKKIIDMRG TDITLKSKKS PRSCMLHRTE LHVNIGGQGR KEHEGQDKPP GMIQRKMCIL FSKPLPSNLK LERATHADEE RLGGKTSFVL PLMPSALPDT EKTADAEARS GDVRKGKPHR SQKENRHEVK TIDMRFRIHC QEARISPMSH ILNAKELVLN INKLEKKVHK DKDEACVVLS RTFLSIPSAP PLYLDSGNKT DKDTPGITGS SCPQRTLHVP SNTQKITNRD SVEGVDKNVV KQAEQYVPRP EAEQQLTSNF MISVQQRNQP SRVRSEEDLN QLVLNSRDED IYFTGFGTIR SGKRPEWLFT GKKAQPVKYK TETLTAFLSY PTMDATKMGG LEEDTEIMDN LNHKISPKAS VSLIRKISKE LYVTLGTPAN SKGFSVSERY AHQQETSSKV SPELAGSCKF DKPKEDGQSN DRISKMFSPK VLAPQTKGSL KKISIVTNWN APQNIEEQDI VMKKQVIRRC EHGHKTRTNT ILSKFPLQSG KQKTPSETDV DKKTTAHLSL QMLPGIHMDM TEIDPAKGGR KQALLISEQE EGVLEFLPKS LFPPWTFQFQ SGDLEEKHQT DANTNINLEQ KKLEMDNDST VNQKEGKLKI GTNRALHLQE EKTEMHKART ANLEKERGRM
Explore Leucine-rich repeat transmembrane protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets